<SEC-DOCUMENT>0001437749-23-034146.txt : 20231212
<SEC-HEADER>0001437749-23-034146.hdr.sgml : 20231212
<ACCEPTANCE-DATETIME>20231212091907
ACCESSION NUMBER:		0001437749-23-034146
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20231212
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231212
DATE AS OF CHANGE:		20231212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		231480125

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sava20231211_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:sava="http://www.sava.com/20231212"><head>
	<title>sava20231211_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 12/12/2023 2:21:41 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20238K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20238K" name="dei:EntityCentralIndexKey">0001069530</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="sava-20231212.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20238K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-12-12</xbrli:startDate>
<xbrli:endDate>2023-12-12</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20238K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section</b>&#xa0;<b>13 or 15(d) of the</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="d20238K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>December 12, 2023</b></ix:nonNumeric></b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityRegistrantName"><b>Cassava Sciences, Inc.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityFileNumber"><b>000-29959</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityTaxIdentificationNumber"><b>91-1911336</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Commission</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identification Number)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressAddressLine1"><b>6801 N Capital of Texas Highway, Building 1; Suite 300</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressCityOrTown"><b>Austin</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>Texas</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressPostalZipCode"><b>78731</b></ix:nonNumeric></b></div>

<div style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Address of principal executive offices, including zip code)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20238K" name="dei:CityAreaCode"><b>512</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20238K" name="dei:LocalPhoneNumber"><b>501-2444</b></ix:nonNumeric></b></div>

<div style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Registrant</b>&#8217;<b>s telephone number, including area code)</b></div>

<div style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<div style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Former name or former address, if changed since last report.)</b></div>

<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; margin: 0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Trading</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:TradingSymbol">SAVA</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8.01: Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">On December 12, 2023, Cassava Sciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing that the Board of Directors of the Company declared a distribution to the holders of record of the Company&#8217;s shares of common stock, par value $0.001 per share (the &#8220;Common Shares&#8221;), in the form of warrants to purchase Common Shares (the &#8220;Warrants&#8221;). The Warrants will be distributed on or about January 3, 2024, to the holders of record of Common Shares as of the close of business on December 22, 2023 (the &#8220;Distribution Record Date&#8221;).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">The foregoing description is only a summary and is qualified in its entirety by reference to the press release, which is filed as an exhibit to this Form 8-K and incorporated herein by reference.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-indent: -18pt;"><b>7.01 Regulation FD Disclosure</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-indent: -9pt;">In connection with the press release described above, the Company posted a Warrant Distribution Q&amp;A&#xa0;on its website, a copy of which is attached as Exhibit 99.2.&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>No Offer or Solicitation</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms of the Warrants will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and will be available on the SEC&#8217;s website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This communication contains a general summary of the warrants. Please read the warrant agreement when it becomes available as it will contain important information about the terms of the Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Forward Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><i>This Form 8-K contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as </i>&#8220;<i>may,</i>&#8221;<i> </i>&#8220;<i>anticipate,</i>&#8221;<i> </i>&#8220;<i>believe,</i>&#8221;<i> </i>&#8220;<i>could,</i>&#8221;<i> </i>&#8220;<i>expect,</i>&#8221;<i> </i>&#8220;<i>forecast,</i>&#8221;<i> </i>&#8220;<i>intend,</i>&#8221;<i> </i>&#8220;<i>plan,</i>&#8221;<i> </i>&#8220;<i>possible,</i>&#8221;<i> </i>&#8220;<i>potential,</i>&#8221;<i> and other words and terms of similar meaning. Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this Form 8-K and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, whether </i>&#xa0;<i>the Company will derive the anticipated </i>&#xa0;<i>benefits of the transaction described in this communication and any unanticipated impacts of the warrant distribution on the Company</i>&#8217;<i>s business operations, and including those described in the section entitled </i>&#8220;<i>Risk Factors</i>&#8221;<i> in our Annual Report on Form 10-K for the year ended December 31, 2022, and future reports to be filed with the SEC. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this Form 8-K are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release. </i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>9.01: Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&#xa0;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">99.1</td>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
			<td style="vertical-align:top;width:auto;"><a href="ex_605372.htm" style="-sec-extract:exhibit;">Press Release dated December 12, 2023</a></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">99.2</td>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
			<td style="vertical-align:top;width:auto;"><a href="ex_605373.htm" style="-sec-extract:exhibit;">Warrant Distribution Q&amp;A dated December 12, 2023</a></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:auto;">&#xa0;</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8206;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>SIGNATURE</b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CASSAVA SCIENCES, INC.</b></div>
			</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a Delaware corporation</div>
			</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: December 12, 2023</div>
			</td>
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</div>
			</td>
			<td style="vertical-align: top; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline;">/s/ ERIC J. SCHOEN</span></div>
			</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Eric J. Schoen</div>
			</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 39%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="vertical-align: top; width: 37%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer</div>
			</td>
			<td style="vertical-align: top; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_605372.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_605372.htm</title>
	<!-- Generated by ThunderDome Portal - 12/12/2023 2:20:32 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="ex_605372img001.jpg" src="ex_605372img001.jpg" style="width:460;height:150;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; margin: 0pt; text-indent: -9pt; text-align: right;"><b>Exhibit 99.1</b></p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 12pt;">

		<tr style="vertical-align: top; font-size: 12pt;">
			<td style="width: 72pt; font-size: 12pt;">&nbsp;</td>
			<td style="width: 18pt; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&#9632;</p>
			</td>
			<td style="width: auto; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><b>Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock </b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 12pt;">

		<tr style="vertical-align: top; font-size: 12pt;">
			<td style="width: 72pt; font-size: 12pt;">&nbsp;</td>
			<td style="width: 18pt; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&#9632;</p>
			</td>
			<td style="width: auto; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><b>All Warrants to Be Distributed to Shareholders Free of Charge</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 12pt;">

		<tr style="vertical-align: top; font-size: 12pt;">
			<td style="width: 72pt; font-size: 12pt;">&nbsp;</td>
			<td style="width: 18pt; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&#9632;</p>
			</td>
			<td style="width: auto; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><b>Warrants Are Expected to List and Trade on Nasdaq</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 12pt;">

		<tr style="vertical-align: top; font-size: 12pt;">
			<td style="width: 72pt; font-size: 12pt;">&nbsp;</td>
			<td style="width: 18pt; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;">&#9632;</p>
			</td>
			<td style="width: auto; font-size: 12pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><b>Warrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AUSTIN, Texas, December 12, 2023 -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warrants to holders of the Company's common stock as of December 22, 2023 (the &#8220;Record Date&#8221;). Shareholders will receive 4 warrants for each 10 shares of common stock held as of the Record Date, subject to rounding. Cassava Sciences will distribute the warrants to shareholders on or about January 3, 2024 (the &#8220;Distribution Date&#8221;). After the Distribution Date, the warrants are expected to list and trade on Nasdaq, separate from Cassava Sciences&#8217; common stock, under the ticker SAVAW.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Many parties are deeply vested in the long-term success of Cassava Sciences, including its directors, management and employees,&#8221; said Remi Barbier, President &amp; CEO. &#8220;We believe a warrant distribution underscores the inherent strength of the Company. It allows our shareholder base to participate in a process of raising capital. We intend to use the cash proceeds from the exercise of the warrants to support our ongoing Phase 3 clinical development of oral simufilam in people with Alzheimer&#8217;s disease.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Details of Warrant Distribution</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stockholders will receive 4 warrants for each 10 shares of common stock held as of the Record Date, rounded down to the nearest whole number for any fractional warrant. As an example, a shareholder who owns 1,000 shares of Cassava Sciences will receive 400 warrants plus, as applicable and as described below, the Bonus Share Fraction. Each warrant will entitle the holder to purchase, at the holder&#8217;s sole and exclusive election, one share of common stock at an initial exercise price of $33.00 per share plus, as applicable and as described below, the Bonus Share Fraction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">After the Distribution Date, warrant holders may cash-exercise their warrants, or they may sell their warrants on the open market. The Company will receive cash proceeds only from warrant holders who exercise their warrants. Warrant holders may exercise their warrants as will be specified under the terms of a warrant agreement that is expected to be filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on or about January 3, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All warrants will expire on Friday, November 15, 2024, at 5:00 p.m. New York City time, unless redeemed by the Company before that date. The warrants will be redeemable by the Company on or after April 15, 2024, upon 20 calendar days&#8217; notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A Q&amp;A regarding this warrant distribution has been posted in the Investor&#8217;s section of the Company&#8217;s website, https://www.CassavaSciences.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Details of Bonus Share Program</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Bonus Share Fraction entitles a holder to receive an additional 0.5 of a share of common stock for each warrant exercised (the &#8220;Bonus Share Fraction&#8221;) without payment of any additional exercise price. After the Distribution Date, the right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time (the &#8220;Bonus Share Expiration Date&#8221;) upon the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period in which the daily volume weighted average price (&#8220;VWAP&#8221;) of the shares of common stock has been at least equal to a specified price, initially $26.40 per share, for at least 20 trading days (whether or not consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon not less than 20 business days&#8217; public notice. Any warrant exercised after the Bonus Share Expiration Date will not be entitled to the Bonus Share Fraction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company will make a public announcement of the Bonus Share Expiration Date (i) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition and (ii) at least 20 business days prior to such date, in the case of the Company setting a Bonus Share Expiration Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The distribution of the warrants has not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), because the issuance of a distribution in the form of a warrant for no consideration is not a sale or disposition of a security or interest in a security for value pursuant to Section 2(a)(3) of the Securities Act. The Company expects to file with the SEC a prospectus supplement, under its existing shelf registration statement, registering the shares of common stock underlying the warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">B. Dyson Capital Advisors is serving as exclusive financial advisor on our distribution of warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Gibson, Dunn &amp; Crutcher LLP is serving as legal advisor to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Cassava Sciences, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing&#8212;but not removing&#8212;a critical protein in the brain. Simufilam, our lead product candidate, is in clinical testing in a pair of Phase 3 clinical trials in patients with Alzheimer&#8217;s disease dementia. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For more information, please visit: https://www.CassavaSciences.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>For More Information Contact:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Eric Schoen, Chief Financial Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(512) 501-2450</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ESchoen@CassavaSciences.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The foregoing press release does not purport to be complete and is qualified in its entirety by reference to the full text of the warrant distribution related agreements to be filed with the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cautionary Note Regarding Forward-Looking Statements:</i></b><i> </i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This Press Release and the Q&amp;A referenced in it contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: the development of new treatment options for people with Alzheimer</i>&#8217;<i>s disease; the long-term success of the Company; the Company</i>&#8217;<i>s ability to raise additional capital while protecting stockholders from excessive dilution; the design, scope, completion, intended purpose, or future results of our warrant distribution; any expected clinical results of our on-going Phase 3 studies of simufilam in Alzheimer</i>&#8217;<i>s disease; the treatment of people with Alzheimer</i>&#8217;<i>s disease dementia; the safety or efficacy of simufilam in people with Alzheimer</i>&#8217;<i>s disease dementia; expected cash use of proceeds from the warrant distribution, if any; whether warrants will be traded on Nasdaq, the price of those warrants and the existence of a market for those warrants; whether and when warrants will be redeemed by the Company; whether the distribution of a warrant is a taxable event; comments made by our employees regarding the warrant distribution, simufilam, and potential benefits, if any, of our product candidates. These statements may be identified by words such as </i>&#8220;<i>may,</i>&#8221;<i> </i>&#8220;<i>anticipate,</i>&#8221;<i> </i>&#8220;<i>believe,</i>&#8221;<i> </i>&#8220;<i>could,</i>&#8221;<i> </i>&#8220;<i>expect,</i>&#8221;<i> </i>&#8220;<i>forecast,</i>&#8221;<i> </i>&#8220;<i>intend,</i>&#8221;<i> </i>&#8220;<i>plan,</i>&#8221;<i> </i>&#8220;<i>possible,</i>&#8221;<i> </i>&#8220;<i>potential,</i>&#8221;<i> and other words and terms of similar meaning. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Simufilam is our investigational product candidate. It is not approved by any regulatory authority in any jurisdiction and its safety, efficacy or other desirable attributes have not been established in patients.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Clinical results and analyses of our previous studies should not be relied upon as predictive of Phase 3 studies or any other study. Our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Forward looking statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of the warrant distribution on our business operations, and including those described in the section entitled </i>&#8220;<i>Risk Factors</i>&#8221;<i> in our Annual Report on Form 10-K for the year ended December 31, 2022, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this Press Release and in the Q&amp;A referenced in it are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at </i><i>www.sec.gov</i><i>.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No Offer or Solicitation</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This Press Release and the Q&amp;A referenced in it shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms of the warrants will be filed with the Securities and Exchange Commission (the "SEC") and will be available on the SEC's website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the warrants. Please read the warrant agreement when it becomes available as it will contain important information about the terms of the warrants.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>###</b></p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_605373.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_605373.htm</title>
	<!-- Generated by ThunderDome Portal - 12/12/2023 1:31:49 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img src="ex_605373img001.jpg" style="width:442;height:144;" alt="ex_605373img001.jpg"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 99.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dear Stockholder </b>&#8211;<b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>I</b>&#8217;<b>m pleased to inform you that on December 12, 2023, Cassava Sciences announced a pro rata distribution of warrants to its stockholders. The warrants will allow the holder to purchase additional shares of Cassava Sciences common stock, if they wish to do so. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>With this Q&amp;A, I would like to make the warrant distribution a subject of conversation, and answer some of your questions.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>But first, I</b>&#8217;<b>d like to address the strategic rationale for the warrant distribution. As you know, Cassava Sciences is a biotechnology company with an unwavering commitment to develop a new treatment option for people with Alzheimer</b>&#8217;<b>s disease. Many parties are deeply vested in the long-term success of Cassava Sciences, including its directors, management and employees. We believe a warrant distribution underscores the inherent strength of the Company. It allows our stockholder base to participate in a process of raising capital. We intend to use any proceeds from the exercise of warrants to support our ongoing Phase 3 clinical trials of oral simufilam in people with Alzheimer</b>&#8217;<b>s disease. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As with any Q&amp;A, this one won</b>&#8217;<b>t answer all your questions, nor is it intended to. For full information, carefully read the warrant agreement to be filed with the U.S. Securities and Exchange Commission (SEC) and all other SEC filings that pertain to our Company and its current operations. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Please reach out if you have questions. I</b>&#8217;<b>d love to hear from you. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>You may email questions directly to me to: </b><b>WarrantQuestions@CassavaSciences.com</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>We</b>&#8217;<b>ll do our best to respond to respectful inquiries, within limits. Given the volume of expected emails, we may not be able to reply to all questions.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As we approach the holiday season, I also want to say how much I appreciate your support. It takes a monumental effort to develop a new treatment for Alzheimer's disease. It gives me tremendous joy to know you</b>&#8217;<b>re with us on the journey.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Respectfully,</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Remi Barbier</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Founder, Chairman of the Board</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>President &amp; CEO</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Why is Cassava Sciences doing a warrant distribution now? </b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>In 2024 and beyond, Cassava Sciences</i>&#8217;<i> strategic goal is to complete the clinical development of simufilam, our drug candidate for people with Alzheimer</i>&#8217;<i>s disease. In approximately December 2024, we expect to have top-line clinical results for one of two on-going Phase 3 trials of simufilam in Alzheimer</i>&#8217;<i>s disease.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Where can I find all the terms and conditions of the warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>The warrants allow the holder to purchase shares of common stock on terms and conditions as set forth in the warrant agreement to be filed with the SEC on or about January 3, 2024 (the </i>&#8220;<i>Distribution Date</i>&#8221;<i>). The warrant agreement will also be posted in the Investors section of the Company</i>&#8217;<i>s website at </i><i>www.CassavaSciences.com</i><i>. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How does it work in practice?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Cassava Sciences</i>&#8217;<i> stockholders will receive, free of charge, a certain number of warrants. That amount is proportional (</i>&#8220;<i>pro-rata</i>&#8221;<i>) to the holder</i>&#8217;<i>s existing ownership of Cassava Sciences common stock. Each warrant will entitle the holder to purchase, at the holder</i>&#8217;<i>s sole and exclusive election, at the exercise price, one share of common stock. Warrant holders may exercise their warrants, or they may sell their warrants on the open market for cash. It</i>&#8217;<i>s your choice.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>What is a warrant?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>A warrant gives the holder the right </i>&#8211;<i> but not the obligation </i>&#8211;<i> to buy shares of common stock of the issuer at a specified price for a specific period. Important terms and conditions for our warrant distribution will be fully disclosed in the warrant agreement that will be filed with the SEC. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Is a warrant the same thing as a share of common stock?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>A warrant and a share of common stock are different. A share of common stock represents equity ownership. A warrant entitles the holder to purchase, at the holder</i>&#8217;<i>s sole and exclusive election, at the exercise price, one share of common stock.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How many warrants will I receive on the Distribution Date?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Each stockholder will receive 4 warrants for each 10 shares of Cassava Sciences common stock held as of the Record Date (that is, 0.4 times the number of shares owned on the Record Date, rounded down to the nearest whole number). Any stockholder owning at least 3 shares on the record date will receive at least 1 warrant.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Will there be a market for the warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>We expect that the warrants will list and trade on Nasdaq separate from Cassava Sciences</i>&#8217;<i> common stock. Once the warrants are listed on Nasdaq, the market will determine any market value of the warrants based on supply and demand or other factors. We cannot provide any assurances that an active trading market for the warrants will develop or continue or that there will be liquidity in the trading market for the warrants, or the price at which the warrants will be able to be resold.</i></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How much cash will Cassava Sciences raise through this warrant distribution and what will it do with the proceeds?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>We don</i>&#8217;<i>t know yet. There are too many variables to accurately predict how much cash, if any, Cassava Sciences may raise through this distribution of warrants. Some key variables are beyond the control of the Company, such as the market value of warrants after they list on the Nasdaq exchange, how many warrant holders will exercise vs sell in the open market, the timing of cash proceeds from the exercise of warrants, etc.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How will Cassava Sciences use the cash proceeds?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>We intend to use any proceeds from the exercise of warrants to support our ongoing Phase 3 clinical trials of oral simufilam in people with Alzheimer</i>&#8217;<i>s disease. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>10.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Will the exercise of the warrants result in the issuance of shares of common stock?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Cassava Sciences will not issue any shares of common stock at the time of the warrant distribution. However, the Company will issue shares of common stock to warrant holders who exercise their warrants for cash. Each warrant is exercisable for one share of our common stock. Stockholders who choose to exercise during a certain period will receive an additional 0.5 of a share of common stock per warrant, without any additional cost (see question #13).</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>11.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>When will the warrants expire?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>All warrants will expire at 5:00 pm New York City time on Friday, November 15, 2024. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Importantly, however, the Company has the option of redeeming the warrants earlier than November 15, 2024, as will be set forth in the warrant agreement to be filed with the SEC and to be made publicly available in the Investors section of the Company</i>&#8217;<i>s website at </i><i>www.CassavaSciences.com</i><i>. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>12.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>What is the exercise price of the warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Each warrant will initially allow holders to purchase one share of Cassava Sciences common stock for an exercise price of thirty-three dollars ($33.00) per warrant, plus, during the Bonus Share Fraction period, the Bonus Share Fraction. The Exercise Price must be paid only in cash and only via your financial institution. If you choose to exercise warrants, please do not send cash or checks to the Company, or to any party other than your financial institution.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>13.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>What is the </b>&#8220;<b>Bonus Share</b>&#8221;<b>&nbsp;program?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>We are offering a Bonus Share program to attract further investment in the Company and to reward stockholders who exercise warrants early on. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Stockholders can choose to exercise their warrants early, that is, during the defined Bonus Share Fraction period. </i><b><i>Those who do so will receive an additional 0.5 of a common share per warrant as a </i></b>&#8220;<b><i>bonus</i></b>&#8221;<b><i> share, without additional cost. Holders who exercise their warrants early and receive a Bonus Share Fraction will have paid an effective price of approximately $22.00 per share of Cassava Sciences common stock.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>14.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>When does the </b>&#8220;<b>Bonus Share</b>&#8221;<b>&nbsp;program begin and end?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>The Bonus Share Fraction period begins on the Distribution Date of the warrants, which we anticipate will be on or about January 3, 2024.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>The Bonus Share Expiration Date will be the earlier of (i) the first business day following the first 30 consecutive trading day period in which the daily volume-weighted average price (VWAP) of the shares of common stock has been at least equal to a specified price (initially, $26.40) for at least 20 trading days (whether or not consecutive) and (ii) the date specified by the Company upon not less than 20 business days</i>&#8217;<i> notice. The full details of the Bonus Share feature will be set forth in the warrant agreement, which will be made available on the Investors section of the Company</i>&#8217;<i>s website at </i><i>www.CassavaSciences.com</i><i>. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>15.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Will you issue fractional warrants or shares in the event the math does not work out to a whole number?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>No warrants will be issued to any stockholder owning fewer than 3 shares on the Record Date. No fractional warrants will be issued.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>We also will not issue fractional shares of common stock or pay cash in lieu thereof. If you are entitled to receive a non-whole number of shares of common stock upon exercise of the Warrants, we will round down the total number of shares of common stock to the nearest whole number. A whole number is any non-negative number, including zero, that is not a fraction or decimal. The Company</i>&#8217;<i>s calculation shall be determinative.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>16.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Is there any cost to stockholders, or any cash payment required from stockholders, to receive the warrant distribution?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Cassava Sciences will distribute warrants at no cost to stockholders who hold at least three shares on the Record Date. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>17.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Do I have to do anything to receive my warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>All holders of record of at least three shares of common stock as of Friday, December 22, 2023 will automatically receive the warrants in book-entry form on or about January 3, 2024. If you hold your shares through a brokerage account, bank or financial institution and are a holder in street name, contact your broker for further information. If your shares are held in a registered account with Cassava Science</i>&#8217;<i>s transfer agent, contact Client Services at Computershare Trust Company, N.A. 150 Royall Street, Canton, MA 02021 for further information.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>18.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Can I sell the warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Yes, you can sell the warrants and pocket the proceeds. The warrants are transferable and are expected to be listed and trade on Nasdaq, as set forth in the warrant agreement to be filed with the SEC and to be made publicly available in the Investors section of the Company</i>&#8217;<i>s website at </i><i>www.CassavaSciences.com</i><i>. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>19.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>If I sell my common stock, must I also sell my warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>You choose what to hold and what to sell. The warrants and the Company</i>&#8217;<i>s common stock are separate securities and will trade independent of each other. You may sell your warrants and hold your common stock, or vice versa. You must be a holder of Cassava Sciences common stock as of December 22, 2023 to receive a distribution of warrants. Once you receive warrants, you do not need to be a holder of common stock to exercise, purchase or sell the warrants.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>20.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How soon can I exercise or sell my warrants?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Stockholders may exercise or sell their warrants immediately after the warrants are issued on the Distribution Date. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>21.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Must I exercise or sell my warrants by a particular date?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Yes. You may exercise or sell your warrants at any time before they expire. All warrants are set to expire at 5pm New York City time on Friday, November 15, 2024, if the Company chooses not to redeem them earlier.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>However, and this is very important, the Company has the option of redeeming the warrants earlier than November 15, 2024. The warrants cannot be redeemed by the Company with a redemption date prior to April 15, 2024. After April 15, 2024, the Company can choose to redeem the warrants for a nominal amount (.01</i>&#162;<i>/warrant) upon a 20-calendar days</i>&#8217;<i> notice. Such notice will be given by Company press release, as described in the warrant agreement to be filed with the SEC and to be made publicly available in the Investors section of the Company</i>&#8217;<i>s website at </i><i>www.CassavaSciences.com</i><b><i> You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>22.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>What happens after the warrants are redeemed or expire?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>After the warrants expire on November 15, 2024, or upon redemption of the warrants by the Company, whichever comes first, the right to exercise the warrants will no longer exist. At that point the warrants will have zero trading value and are expected to be delisted from Nasdaq. Of course, Cassava Sciences common stock will continue to trade on Nasdaq.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>23.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Will I owe taxes on this distribution?</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Cassava Sciences intends to structure this warrant distribution as a non-taxable distribution under section 305(a) of the U.S. Internal Revenue Code. Tax law and accounting rules are complex and can vary from state to state and person-to-person. Cassava Sciences does not provide, and does not offer, any advice regarding the tax or accounting treatment of our warrant distribution or its impact on your personal finances. This Q&amp;A is for informational purposes only, and is not intended, and should not be relied upon, for tax, legal or accounting advice. You should consult with and rely only on your tax, legal and accounting advisors prior to engaging in any transaction related to this warrant distribution. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>24.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>What is the Record Date for the distribution of warrants? </b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Friday, December 22, 2023.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>25.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Where can I get more information regarding the warrant distribution? </b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Additional information regarding the terms of the warrants, including the warrant agreement, will be filed with the SEC on the Distribution Date and will be available in the Investors section of our website at </i><i>www.CassavaSciences.com</i><i>. </i><b><i>You should carefully read the warrant agreement and the other documents filed with the SEC by Cassava Sciences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The foregoing Q&amp;A does not purport to be complete and is qualified in its entirety by reference to the full text of the warrant distribution related agreements to be filed with the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cautionary Note Regarding Forward-Looking Statements:</i></b><i> </i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This Q&amp;A contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: the development of new treatment options for people with Alzheimer</i>&#8217;<i>s disease; the long-term success of the Company; the Company</i>&#8217;<i>s ability to raise additional capital while protecting stockholders from excessive dilution; the design, scope, completion, intended purpose, or future results of our warrant distribution; any expected clinical results of our on-going Phase 3 studies of simufilam in Alzheimer</i>&#8217;<i>s disease; the treatment of people with Alzheimer</i>&#8217;<i>s disease dementia; the safety or efficacy of simufilam in people with Alzheimer</i>&#8217;<i>s disease dementia; expected cash use of proceeds from the warrant distribution, if any; whether warrants will be traded on Nasdaq, the price of those warrants and the existence of a market for those warrants; whether and when warrants will be redeemed by the Company; whether the distribution of a warrant is a taxable event; comments made by our employees regarding the warrant distribution, simufilam, and potential benefits, if any, of our product candidates. These statements may be identified by words such as </i>&#8220;<i>may,</i>&#8221;<i> </i>&#8220;<i>anticipate,</i>&#8221;<i> </i>&#8220;<i>believe,</i>&#8221;<i> </i>&#8220;<i>could,</i>&#8221;<i> </i>&#8220;<i>expect,</i>&#8221;<i> </i>&#8220;<i>forecast,</i>&#8221;<i> </i>&#8220;<i>intend,</i>&#8221;<i> </i>&#8220;<i>plan,</i>&#8221;<i> </i>&#8220;<i>possible,</i>&#8221;<i> </i>&#8220;<i>potential,</i>&#8221;<i> and other words and terms of similar meaning. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Simufilam is our investigational product candidate. It is not approved by any regulatory authority in any jurisdiction and its safety, efficacy or other desirable attributes have not been established in patients.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Clinical results and analyses of our previous studies should not be relied upon as predictive of Phase 3 studies or any other study. Our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of the warrant distribution on our business operations, and including those described in the section entitled </i>&#8220;<i>Risk Factors</i>&#8221;<i> in our Annual Report on Form 10-K for the year ended December 31, 2022, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this Q&amp;A are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this news release. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at </i><i>www.sec.gov</i><i>.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No Offer or Solicitation</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This Q&amp;A shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A Form 8-A registration statement and prospectus supplement describing the terms of the warrants will be filed with the Securities and Exchange Commission (the "SEC") and will be available on the SEC's website located at http://www.sec.gov. Holders of Company common stock should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the warrants. Please read the warrant agreement when it becomes available as it will contain important information about the terms of the warrants.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>###</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sava-20231212.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/12/2023 2:21:46 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:sava="http://www.sava.com/20231212" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sava.com/20231212">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231212_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231212_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231212_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.sava.com/20231212/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="sava_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>sava-20231212_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/12/2023 2:21:46 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.sava.com/20231212/role/statement-document-and-entity-information" xlink:href="sava-20231212.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.sava.com/20231212/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>sava-20231212_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/12/2023 2:21:46 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>sava-20231212_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/12/2023 2:21:46 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.sava.com/20231212/role/statement-document-and-entity-information" xlink:href="sava-20231212.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.sava.com/20231212/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex_605372img001.jpg
<TEXT>
begin 644 ex_605372img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 <P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/4****R+"BBB@ KY@_:._P"2AZ?_ -@J/_T;+7T_7S!^T=_R4/3_ /L%1_\
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M8]A^&_PHLK_2X-<\0QM,+@;[>S)*J$[,^.23U Z8]:]9MO#FB6<8CMM'L(E
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M_@K2/"!N?[)^TJMSM\Q99BXR,X(ST/-=%15<TK6OH*RO<****D85\P?M'?\
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M1G:KHH#?0$ ?C1&TU%R&[JZ1>TGP'X^UW38=3O?&5U9O<H)%A\V1B%(R,[6
M!QV%:'CGQ-KG@/P5I&CKJ'VG6KA666^.6;:O5AN_B.Y1D].:U?#/Q7\+3>'K
M-=0U%;*[BA6.6&5&^\  2"!@@URWQF1->T+0_$^EL;G35$D;2JI  8C:QSR!
ME2/RI+F<TIK0'91O%D-SX2\<V.A2:W_PFTK7D41N'M!=.2,#)&=V"<=L8K9T
M[XE:G=_"'4M9.PZO8N+8R[!M)8J%DQTSANG3(KF-/T;X17EC'/-K6H6LK*"\
M,TI#(>XX3!_"N]T#2O!&F_#_ %BXL9KB_P! GWM=-+EB=@P=HP#QC\Z<FK:K
MKV"-^AP>@>'+SQ9I*:QJ7Q%:UN92VV![@EDP2,-EUQZX [UZGX#T+6]"L[N+
M5]<_M>*1U:UEWLVU<<CYL]_<UY5/X;^$TMO+/#XHO$.PE4;E@<<#!3)K<^ =
MQ>O#K-LS2-8QF-D!/RI(=V0/3(QD?2BHFXM_H$-&CV>BBBN0V"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OF#]H[_DH>G_\ 8*C_ /1L
MM?3]?,'[1W_)0]/_ .P5'_Z-EH ^GZ*** "BBB@ HHHH X/7? MW?WSO8W%O
M%;.V_9)G()Z]!TK*_P"%::K_ ,_EG_X]_A7J-%5SL]*&;8F$5%/;R/+O^%::
MK_S^6?\ X]_A1_PK35?^?RS_ /'O\*]1HI\[+_MG%]U]QY=_PK35?^?RS_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVC_AH[P?_P! W7/^_$/_ ,=HHH /^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\
M0-US_OQ#_P#':** #_AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\
MQVBB@ _X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=HHH /^&CO
M!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':** #_AH[P?_ - W7/\
MOQ#_ /':/^&CO!__ $#=<_[\0_\ QVBB@ _X:.\'_P#0-US_ +\0_P#QVC_A
MH[P?_P! W7/^_$/_ ,=HHH /^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US
M_OQ#_P#':** #_AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVBB
M@ _X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=HHH /^&CO!_\
MT#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':** #_AH[P?_ - W7/\ OQ#_
M /':/^&CO!__ $#=<_[\0_\ QVBB@ _X:.\'_P#0-US_ +\0_P#QVC_AH[P?
M_P! W7/^_$/_ ,=HHH /^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#
M_P#':** #_AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVBB@ _X
M:.\'_P#0-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=HHH /^&CO!_\ T#=<
M_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':** #_AH[P?_ - W7/\ OQ#_ /':
M/^&CO!__ $#=<_[\0_\ QVBB@ _X:.\'_P#0-US_ +\0_P#QVO'/BSXUTWQW
?XJM=4TN"[A@BLDMV6Z158L'=LC:S#&''?UHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex_605373img001.jpg
<TEXT>
begin 644 ex_605373img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 ;H# 2(  A$! Q$!_\0
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MY]Y/SK5LKQ;V'S I0_W3UJZ>+H59<L)79G.A4IJ\E8LT445TF04444 %%%%
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M#?Q#@U-63:S>3,,_=;@UK5S25F>C3ES(^?/C?K$MWXK@TH']Q9PA\ ]7?O\
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M1E)%P?:IZ*!IM.Z/)+VTDL;R6VE&&0X^H[&H*[GQAI/VBV%_"N9(AA\#JO\
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M3TG3HM(TFTTZ#)BMHEC4GO@=:N5S/?0V04444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EI* %HHHH **** "BBB@" V=J3DV\63_L"C[%
M:_\ /M%_WP*GHH*YI=R#[%:_\^T7_? H^Q6O_/M%_P!\"IZ* YY=R#[%:_\
M/M%_WP*7[);?\\(O^^!4U%%Q-M[D/V2V_P">$7_? H^R6W_/"+_O@5-13NQ$
M/V2V_P">$7_? I5MX$8,D**PZ$**EHHNP"BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4E+24 +1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966957590896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Cassava Sciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec. 12,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-29959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">6801 N Capital of Texas Highway, Building 1; Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>sava20231211_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sava-20231212.xsd" xlink:type="simple"/>
    <context id="d20238K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20238K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20238K">0001069530</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20238K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20238K">2023-12-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20238K">Cassava Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20238K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20238K">000-29959</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20238K">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20238K">6801 N Capital of Texas Highway, Building 1; Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20238K">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20238K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20238K">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20238K">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20238K">501-2444</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20238K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20238K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20238K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20238K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20238K">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20238K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M4$L! A0#%     @ 8TJ,5P=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !C2HQ78D,E&N\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !C2HQ7F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &-*C%<2.C:*900  ,P0   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !C2HQ7GZ ;\+$"  #B#   #0              @ &I#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( &-*C%>7BKL<P    !,"   +              "
M 84/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &-*C%<ZJJ+G0 $  #P"   /
M              "  6X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !C
M2HQ7)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !C2HQ799!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sava20231211_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sava.com/20231212/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20231212.xsd</File>
    <File>sava-20231212_def.xml</File>
    <File>sava-20231212_lab.xml</File>
    <File>sava-20231212_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="sava20231211_8k.htm">sava20231211_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sava20231211_8k.htm": {
   "nsprefix": "sava",
   "nsuri": "http://www.sava.com/20231212",
   "dts": {
    "schema": {
     "local": [
      "sava-20231212.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20231212_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20231212_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20231212_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sava20231211_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.sava.com/20231212/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231211_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20238K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231211_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sava.com/20231212/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-23-034146-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-034146-xbrl.zip
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M$J"%:5FI'2V\+#3(*#1$C7(%@6>%N(1+AB^HV(FY-1EUKZZ5C6!9^S#HJJ(
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MBKI)@B2MK[*;E76"-!0=252"1U%J7".\;9 T<?/JM];DI(%+8WL@^EA ]&B
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MF'2%V9#.F-S71&[,L7;8V-6)7.I4H6Q113M.1V>9BC7'U=19SEVAS'L=MD4
M["T^ Z:M(6;__,R"P"Z:0LE4^EO?JE1:<O$/BM!^Q<OPZCN>^E/I,63.HZ/,
MH)D"Y41Q*0%.)9J(3I(1BP8E\[8ZU>C]TXS"U9IU' 2+-.RB(4Z-R3?8(@NA
M)W?2X5?G?K)\IND^1_AA!=#G4Y8^2)Y23SKT]6^H2@Q^;3U.A:_/H\<9=TUQ
M+875'")_#G]+6Y\_)[3N_MJ=23=RM=GP;LHJ.B?1S9:&FL_W)H=3EEZG7Q^A
M\/K M[_/ODD)78T!,4 P)<K<&C]SB:4U^!^U:WE!]W2AXND'6="]G591X@!I
M\+%R$7"8G<5/!Z[!<QSM #7W/2O^:*QXL,E<B2Q R73;Q+\:K["(X0 S=-='
M[?FFV9@]"K,@%&OA[%IMLPXP^W@]9"*H?2H7+B/&-ER%NI<7T NHR0W=QZLL
M5[X'Y/;%X JC\TTEX<@;AG$5=4 D5R3:8A"-E3>)DM.:3:&@9:.N7%G$U-W:
M/'595U K3=^JNE>=AXLI@\RUXDJN(':)4EZ'((%>]:Y!0<CZC=]43(AK Y6V
MBBC"=T=I-^<CO&"^='C7[\.NI8SCPT?W9!U835<07T!O%N6O5QBR6"'PQ!A]
M+*]%*I=,]>SH1"BP52ANQM>@77.9>1#UKM#)ZP-74'*DT>-?R/^BK,,1FC'_
M;;+I,CFO'?@BC2PRU[]2OMG(5P0A(Z)5"VGC(!?#Y,GGW RU==WY?'OE>[SL
MF0P1!;ICC4_[Y%'"HK"_69&W"#; WRV-0CP*KRW'*K0M*EN0CH/YK#Q\'Y,6
M+I+F'[U05@OD*8:-(U<8<2U(>3T2*4PN[4V(YSWI"'8FI^([_O)K3'>BQ#CZ
M/YY*ZW.]O<3O.91!:R%?Y0NYH O9<]89T2'F@^G@R]*C_M:SN#?&#!BMAYG;
MU&3&MFM,AYJHV\SXP[I9<FL,S2!,&GN2^V@D-\ADAM9EBPM5B@P-@BU&UN.K
M&P--_Q#U?8IFO/,F"7G[4O&U.VL9B4VP^K:$K*W7Z&S/>ZQ=M3-U2^L224!W
M*Q#D$T3/_]1I+=5UZ3'C;>5*/5]U.Z7D0:!L+B<:Q-9&QD91U09+9GVCL1=9
M,8V2DQGA0*%TC%DE5I4KW"G8>KP_)E(AFX-R%'$\NZH@UN)C?4#<5C/JY&/O
MQR>ZYTRG3R0M.&IC+TR)8E7 J.?&8H&-\4_&O,-_7Z)Z1EMQ4E.;/KM1A/\0
M(\=<Y99Z1=&QFB\MHR&G?LBN'G(;5YM?@]W=8A'2,IQ0)^=*)-+.,(L*M4O7
MODCXI=57"*F732#,3_"'O[SME:*(YO.(CO?TN^\>^70C]+SQ$!1=_(8Z,>7Y
MZDRSGG3BZV]T+@;/8=U:FFG17,[V/F5\3^G3:-<;(]?!,N(1.C*Z7H3372X%
M.=,IN?*,KW7>+K0A"XT)7<L$B!.7K$0^0BO=<O"3LJ^NL6.,HXEU2B?OU$_;
MP7:/A(M,00'8!#%TNU/0AH/"3%;1>45FCG!'^0Z5_914T]H*N7:]N7]U[5IS
M5\)I4>]_KSG/IV-->)^MPGLI$#_E:7T6L<Z4Q4(C,.YHM3:@?_/KS8I@3E'%
MV7OK9:@W+6FHA7\J0M;[6E(FF677KN]HE1DS;D,T&IF<E2\'W+LRI?U"TS&'
MN6&!SOX(MG@NFU<W*8S-Q6YTTV0PD5%V[BE9HAO8@._BP5%P4LU**7<+27C4
M[-S(!QJ7M!TXXES--0&5OV? 'TS8DK@". $1/-;H9.509+P3O(UC*TJ%Q>"[
MNJ[ $I0N5U\9T+T+%UX8=>_![35HZF'L;C=#>]35#8TBE -W-^'CN+L-2BAP
M6F]HQ7BQNTV1ROR&%@9@"O;^IE9^__K-J$X=DP;M IWP(/##(= 8)Y(IB8G0
MGVQ9JEOPZ<L&J1P=9R[KY=DE6D'[QQMO#:Z3<[&2TA6?9D1QH##,O#4@K(#8
MDACKK\G!9V^!&SN\MR-D^* DRO Y:H%GN.X'&8Z/W"]]CJ%C7Q8;6@%28)S0
M0+N$)5N@!4R^^=.C,__$W7IJJT5' N%+80'U+"91Z=]9R($]-"G%S29ZD< +
M"W]E-^S NU%3HU$*EV'649/HC1=%2ALE_@:FIB-?>JA='GZ]7P)H?V FF O5
MY>1DKX8SM7+*->BIKK2I7,W.MUK3$2/]S2]TI]]\71+@'%P^/_CC:B)^P:#E
M_D!8TN& FS$<HH5:NYD! =N/0</!CV3HE-2C6C:QW6^B3A2^",]2O" =AH+A
M+6L]L#N$.E&Y8V&IH1XB+$QT;^GII.FE$KAOE<<5+P[7YB<[09?C^,5PJ("7
M=+$P$*_$A']_&RC5(*B(?NXPQ5#44&M9Z!X?NFV,-H<=*Q397EF\1M6+79+E
M>!(!K'G+9A?G4R"];$M"A_.!2:TN7*'D.T]@M0@?U]6M$#K5L@Y2JOWPKIJ]
MI9O=L)!(BR*!9$'HJ')?FK^.[,<+SSCDH*T\C>I;JQO%9>2E,_H4:^X^)19'
MUE(<\'IIQ'JZ!,W;$.IC6U-9W@H9@#U+L?(1);2#[ J#*2D-@61C?Z6U1H3?
MA/2-=)4HF8)X'(2L[;(5NPRKO!%_8N_LZYOJ>K(C[W)=J FT&"Z=Y;QGKV75
M,R2']\+&@NFMKLC1%31>P=J*YWQ%74_4T-SU>9Y7Y);EVV%RU-\S,3T<_Z-V
MCZP DP3K4K7OX7A*OH<C'F:M5N%'=IA<1-=@Y!2'YT&+C&37<$@ _4=AW?P%
M>ZP.1]XR2/??1&750D_<:;IU.&B,+8+QO'ZKGH_^:3B9&.;"O89C>>,)+WE"
M6\P'7 R/")*N.Z]<?=UYRPY!\>=Y0O<EIZNF1WH[(+[!B\9&WKG:F3BOB9\[
M5H^TON(S-HTQ"0;QQ&MFQK5KUE&\$YS35#<G:OML)N(\0N<9_(J>YU67!9!/
MF#CBKO5HF*6WC?10ZQDH^@65]*S+5( 0E\HE%86A*^.ESF@W26 /WG58#.@:
M1&]&C3E%0,6,*/08S3'HC=YU#%PP";4VJ0V*$R2.3?G.71W.HR<S_!:ZL5N[
M3>\C+]>2$;WK:^>RT(!B"]>AH5!9C1+1^P75X/E7V\(X 2DF"W,5;.Z?*&_=
M8(I\8<0O=/9A;RY-BL!.F_*!DCS?U\K(M7Y"<3\J)D E;BG4)*39A<LX76O\
M)+>VVLTJ(+J<2X!U[HA%>0I%.3,?!8&K,3)ZZ.,@&7BYH^_4)1-)V_?!+]TQ
M6/[VD@[G#&4\($:0-IMP#JY58.OVWJX?R59DD&=585#P"<?36W'7&X>'Q9J(
M&WT[/N_V4E-L$(60IY<HKN-%K?S$L\J=;K.M3K%NMN(S?_<A&H,R[="NB_=3
M*W$ !'=P?XN;;"--IB9B!T4IDK(L3AX\:-%F4W48TQ-#@'L[CM&#1.T0VSSU
MVG/6=PNVQ8%:=/#FY3@(' :=-C3(KA\&SYO.?8A2)Z*]L:1+L0!9B>Z.J[(,
MO0.]%9^(E_S*#I\>&>8T*CD<BMHL*; %73;!G,@CZP2'#AZS1+QUWS]5]&MA
M3Z0PHFX3'G[QQ1<?P:T9ZRL0RD$V^O[@I_/+U^.7YS\^&__PZMGY/P[..D]?
M_OC\]:O>;\E\;,UR_4<,\A O?WSQKY^;WJ %M-OT!XSBP<S$*YAV4F;IV?\#
M4$L#!!0    ( &-*C%<:;#UY9 ,  &\-   1    <V%V82TR,#(S,3(Q,BYX
M<V3-5]MNVS ,?1^P?]#\KBAVU@()FA;%NA4!VFWH!=A;H=A,(LR6/$ENVK\?
M)5\2MT[KY&$8$""2>$@>4A0EGYP]92EY!&V$DM,@' P# C)6B9#+:7!_2\]O
MO\QF 3&6RX2G2L(TD"HX._WXX>03I9<@07,+"9D_D[M5(1/0%RH#\E-IRU-"
M21@Q_$7#:$2B211./A^3\VM*G?Z3228F7D'&"9*09O(TUZF8!BMK\PECZ_5Z
MX%8&2B_1P'#$A'0T8@AJO$E:Z/6HQH;LU_75K;?=@%,A?W?!P_%XS+RTAAJ;
MZP;I*1B(!TOUR)S$!U-#7QEM,W;B.3<-X\1J:I]S,-TZ*&9.[%P,Z3"D41AL
MY2:Q;5:5FR-6"ALG(+K9HZ!%/E:%M/JY&UP)6PI&Q#OR(N*VY4)K+*-=IBMI
M2P6>XE4WW$G:-/@C;R70+0QBE7E4&(510+BU6LP+"]^4SBY@P8L4LU?(/P5/
MQ4) @G6>0@;2M@!;8LOU$NQWGH')>0SO.*P+6F0YECZ1G6J[RKD\!5<JYM8?
MPYTJ;D9K/>J6:!C143A UP';F\.8:94"D[!T9[@?CU3KEI9C,78LPN.>+':=
MJ"[O9B?>CZ@;'1)\YTG;1> ]33\W^T3_ZN3VK(!:P27]Z)!T;UI KVS7<#?8
M)]=O=))>?K=5ZLG!_C?-J5^%57 W.#SF=HOK%_2V3C,[F,)6V^SEOL'[4=MM
MY9A+J:RW45/A>2[D0KFIN^LF]85W POB[]0)U[%K%V_?O"S7*@=M!9CM.],;
M6&E83 /7<6G=;1]2/A_@75!#7CEH=TW?KE %TJL-O5K7G5TTCSE-H4SQOPPD
M@<6^@:"*D,)MPG\73:YAWVA0Q> ES/>+QZG>H8@(? 'B;6C]34X3%1=^@(]5
MBO_"/E-7GCKS]@/B].YO9F_?Y26Q_E8;5IN=*1\J?1Z&I\/A$)_)%Y6/[>&Y
M3,A7[X[,-NY.V M?C?O"0/)#GOIQS-.X2)NL5DH5HDNA757OXU_NVRL-UMHH
MO_*B8;#NEE(]RPB?&ZMYC(\RJPLL.[_5N%</=8(P/V5Z9MM;[+KB-'@'(U)L
M!ZXX2].F0%_"%DYZJ5613P/_+3(16 +X$O1%6*X@)_PTFN&Z"PO+U*_B(1$J
MN?.XI-"E&]8$6?9?G/X%4$L#!!0    ( &-*C%?!0!;]UP0  .8L   5
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M(R>LA[60>8\'C-O(?1?XJ-GW05RVQ\U[%_*X&8NQ"Q\YXQW(HV;\B(_LC&W
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M^0*373[C5:%76>Y8G?MMNB3% @QY7AW,Z3O@/@>Q0#&^"KZ12XRC%2EVQI=
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M%KM.9SL.\84DV/"/3Z<2]:/^LQ?O_ M02P,$%     @ 8TJ,5^F^JY"7%
M3HH  !,   !S879A,C R,S$R,3%?.&LN:'1M[5WK<^*XLO^\4W7_!]WLW3V9
MJO PY 7)4,40,ILS,TD.L'>W[I=3PA:@C;&]DIW ^>MOMR0;FS=Y)\/6S&9
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M/2(!H;VL%Z/V=29*U?3E7-8+S;8WWP@M DWWAY\^_/33:8C9I-II*!Z;))P
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MX5L*.=]*:'OA.9@68/BV"%N=(T'S#1AAILH?IPYYN"34(PRDT\?D9E_X=^$
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M_ZWWR+!_61\=?<!,-L?!2P7*(ZKJ.!=3B]"S( NDV;IHD'_FP9W_[:IY>5K
MA[>>_ ^W=5^%M7C1;=/$R[JX$>R!S[:APW8'_' [H#'@K)>J+[E2OYY O.ZM
M\-(G7^;0XUN]W<E-#G'F'C(]ZN%13 3\PRQ_$ [=VO\#4$L! A0#%     @
M8TJ,5^YVTP!-$P  \E(   T              ( !     &5X7S8P-3,W,BYH
M=&U02P$"% ,4    " !C2HQ7&*7JESL=   :K   #0              @ %X
M$P  97A?-C U,S<S+FAT;5!+ 0(4 Q0    ( &-*C%<:;#UY9 ,  &\-   1
M              "  =XP  !S879A+3(P,C,Q,C$R+GAS9%!+ 0(4 Q0    (
M &-*C%?!0!;]UP0  .8L   5              "  7$T  !S879A+3(P,C,Q
M,C$R7V1E9BYX;6Q02P$"% ,4    " !C2HQ7$LSEH?<%  !$/   %0
M        @ %[.0  <V%V82TR,#(S,3(Q,E]L86(N>&UL4$L! A0#%     @
M8TJ,5XN,DRMS!   ?BT  !4              ( !I3\  '-A=F$M,C R,S$R
M,3)?<')E+GAM;%!+ 0(4 Q0    ( &-*C%?IOJN0EQ0  $Z*   3
M      "  4M$  !S879A,C R,S$R,3%?.&LN:'1M4$L%!@     '  < OP$
' !-9      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
